Dynamic LVOT Obstruction in Sepsis and Beyond

The diagnosis that punishes you for doing what you normally do

Emergency Medicine · Seminar week 1 · released March 23, 2026 · includes a discussion video

When inotropes kill: why 1 in 50 septic shock patients needs the exact opposite treatment. SAM, Venturi physics, and the STOP-FILL-SQUEEZE algorithm.

Learning Objectives

1. Recognize the pathophysiological mechanisms behind dynamic left ventricular outflow tract obstruction (LVOTO) — including systolic anterior motion (SAM), hypovolemia, and catecholamine excess
2. Identify the clinical presentation of LVOTO in septic shock and distinguish it from other causes of refractory hypotension
3. Interpret bedside ultrasound findings diagnostic of dynamic LVOTO — including SAM, dagger-shaped CW Doppler, and elevated LVOT gradients
4. Apply the correct management algorithm: volume resuscitation, afterload augmentation, discontinuation of inotropes, and consideration of beta-blockade
5. Evaluate the prevalence and mortality impact of unrecognized LVOTO in critically ill patients

Section 1: Introduction — The Diagnosis You're Missing

Duration: 10 min | Content Tier: Teaching Point

%%FIG0%% Dynamic left ventricular outflow tract obstruction is one of the most dangerous diagnoses to miss in the emergency department and ICU — not because it is rare, but because its treatment is the exact opposite of what you would normally do for a hypotensive patient.

Teaching Point: Consider a patient in septic shock who is hypotensive despite aggressive fluid resuscitation and vasopressors. Your instinct says: give more fluids, start an inotrope. But if this patient has dynamic LVOTO, that inotrope will kill them. Dobutamine increases contractility, worsens SAM, and accelerates the obstruction. The gradient rises, cardiac output drops, and the patient spirals toward cardiac arrest.

This is not a theoretical concern. Balik et al. screened 527 septic shock patients over 29 months and found that 1.9% — roughly 1 in 50 — had severe LVOTO with systolic anterior motion and significant mitral regurgitation (PMID: 32488425). Li et al. reported ICU mortality rates reaching 53% in septic shock patients with LVOTO, largely driven by delayed recognition and inappropriate catecholamine use (PMID: 41316420).

Say Out Loud: "Every patient in refractory shock gets a bedside echo before I escalate inotropes. Every single one."

Nuance: Historically, LVOTO was considered a disease of hypertrophic cardiomyopathy (HCM). We now understand that dynamic LVOTO occurs across a spectrum — from patients with thick, hypertrophied ventricles to those with structurally normal hearts placed under extreme catecholamine stress (Mingo et al., PMID: 16290226). This paradigm shift is critical for emergency physicians.

Audience Poll: Have you ever encountered a patient whose hypotension worsened with inotropes?

• A) Yes, and I recognized LVOTO
• B) Yes, but I didn't understand why at the time
• C) No
• D) I'm not sure what LVOTO is

Section 2: Pathophysiology — Why the Outflow Tract Obstructs

Duration: 12 min | Content Tier: MUST ACT

%%FIG1%% MUST ACT: Understanding the mechanism of LVOTO is essential because the treatment flows directly from the physiology. Get the mechanism wrong, and you will treat the patient backwards.

The Three Ingredients for Dynamic LVOTO

Dynamic LVOTO requires a convergence of factors that create a "perfect storm" in the left ventricle:

1. Venturi Effect and Drag Forces: During systole, blood accelerates through the narrowed LVOT. This high-velocity flow creates a low-pressure zone (Bernoulli principle) that pulls the anterior mitral valve leaflet toward the septum — systolic anterior motion (SAM). Once SAM occurs, the obstruction becomes self-perpetuating: obstruction → higher velocity → more drag → more SAM.

1. Predisposing Anatomy: Patients with LV hypertrophy (from hypertension, HCM, or aortic stenosis) have a narrower LVOT at baseline. Basal septal hypertrophy is the most common structural predisposing factor. However, even patients with normal anatomy can develop LVOTO under extreme physiologic stress (Mingo et al., 2006; PMID: 16290226).

1. Physiologic Triggers: The acute precipitants that convert a predisposed LVOT into an obstructed one:

• Hypovolemia — reduces LV cavity size, narrows the outflow tract
• Tachycardia — shortens filling time, reduces preload
• Low afterload — reduces opposing pressure, allowing greater obstruction
• Catecholamines — increase contractility, accelerate ejection velocity, and worsen SAM

Decision Point: In septic shock, all four triggers are present simultaneously: the patient is hypovolemic, tachycardic, vasodilated (low afterload), and receiving catecholamines. This is why sepsis is the perfect breeding ground for LVOTO.

Teaching Point: Slama et al. in their authoritative review emphasized that LVOTO is "not unusual in ICU patients, particularly with septic shock" — the combination of hypovolemia, low systemic vascular resistance, and inotropic support creates an iatrogenic perfect storm (Current Opinion in Critical Care, 2016; PMID: 27054628).

Structural vs. Physiological — A False Dichotomy

Nuance: Evans et al. argued that the traditional distinction between "structural" (HCM) and "dynamic" (stress-induced) LVOTO is misleading. Many patients have subclinical septal hypertrophy from years of hypertension that was never diagnosed. When they develop sepsis, the combination of their subclinical anatomy and acute physiologic changes produces clinically significant obstruction. Risk factors include: elderly age, female sex, hypertension, diabetes, and chronic kidney disease (PMID: 28072930).

Say Out Loud: "LVOTO doesn't just happen in HCM patients. Any thick ventricle plus hypovolemia plus catecholamines equals obstruction risk."

Section 3: Bedside Diagnosis — The Echo Findings That Save Lives

Duration: 12 min | Content Tier: MUST ACT

%%FIG2%% MUST ACT: Bedside transthoracic echocardiography is the definitive diagnostic tool for LVOTO. You cannot diagnose this condition clinically — the physical exam findings overlap completely with other causes of cardiogenic shock. The echo findings are specific and actionable.

The Four Key Echo Findings

1. Systolic Anterior Motion (SAM): In the parasternal long-axis (PLAX) view, watch the anterior mitral valve leaflet during systole. In LVOTO, the leaflet is pulled toward the interventricular septum, contacting or nearly contacting it. This is pathognomonic.

1. Hyperdynamic Left Ventricle: The LV walls contract vigorously, often with near-cavity obliteration in systole. This is the opposite of the hypokinetic, dilated ventricle you see in cardiogenic shock from pump failure — and this distinction is life-saving.

1. Dagger-Shaped CW Doppler: Continuous-wave Doppler across the LVOT in the apical 5-chamber view shows a late-peaking, concave ("dagger-shaped") velocity profile. A gradient ≥30 mmHg is significant; ≥50 mmHg is severe and requires immediate intervention (Long et al., 2025; PMID: 40876217).

1. Mitral Regurgitation: SAM distorts the mitral valve, creating posteriorly-directed mitral regurgitation on color Doppler. The severity of MR correlates with the degree of obstruction.

Framework:

Teaching Point: Harrington et al. described three cases where LVOTO mimicked cardiogenic shock post-MI. In each case, conventional cardiogenic shock management (inotropes, even mechanical circulatory support) worsened the patient. It was focused bedside 2D echo by critical care physicians that identified the correct diagnosis and changed management (Journal of Intensive Care Medicine, 2023; PMID: 37287244).

Say Out Loud: "Before I start dobutamine or milrinone on any shock patient, I am going to look at the LVOT in the parasternal long-axis view. It takes 30 seconds."

Audience Poll: How confident are you in identifying SAM on bedside echo?

• A) Very confident — I've seen it multiple times
• B) Somewhat confident — I know what to look for
• C) Not confident — I've never specifically assessed for it
• D) I don't know what SAM looks like

Section 4: Prevalence — More Common Than You Think

Duration: 8 min | Content Tier: Teaching Point

%%FIG3%% Teaching Point: The prevalence of dynamic LVOTO in critically ill patients is higher than most clinicians realize, primarily because we don't routinely screen for it.

The Data

• Septic shock: Balik et al. found 1.9% (10/527) of septic shock patients had severe LVOTO with SAM and mitral regurgitation. This likely underestimates true prevalence, as only patients with hemodynamically significant obstruction were captured (PMID: 32488425).

• Takotsubo syndrome with shock: Vila-Sanjuan et al. studied 322 Takotsubo patients with cardiogenic shock in the largest multicenter study to date. 18% (58/322) had LVOTO, associated with higher rates of ventricular arrhythmias (15.5% vs 8.7%) and acute kidney injury (PMID: 39209437).

• Post-operative cardiac patients: Patients after mitral valve repair, aortic valve replacement, and septal myectomy are at elevated risk. Altered geometry and loading conditions create susceptibility that persists for days to weeks post-operatively (Bughrara et al., PMID: 32008647).

• Structurally normal hearts: Mingo et al. documented LVOTO in patients with no baseline hypertrophy, gradient, or SAM — purely from catecholamine excess. This is important: you cannot rule out LVOTO based on the absence of structural heart disease (PMID: 16290226).

Nuance: The mortality impact is staggering. Li et al. reported ICU mortality of 53% in septic shock patients with LVOTO — far exceeding baseline septic shock mortality of 25-30%. This excess mortality is likely driven by delayed recognition and paradoxically harmful treatment with catecholamines (PMID: 41316420).

Section 5: Management — The Algorithm That Saves Lives

Duration: 12 min | Content Tier: MUST ACT

%%FIG4%% MUST ACT: The management of dynamic LVOTO is counterintuitive and directly opposes standard shock management. Memorize this algorithm — it will save a life.

The STOP-FILL-SQUEEZE Framework

Framework:

S — STOP the offending agents

• Discontinue dobutamine, milrinone, and other inotropes immediately
• Wean catecholamines if possible
• Stop diuretics
• Consider weaning mechanical circulatory support (IABP can worsen LVOTO by reducing afterload)

T — TREAT the tachycardia

• Tachycardia shortens diastolic filling time and worsens obstruction
• Short-acting beta-blocker (esmolol) if hemodynamics tolerate
• Correct atrial fibrillation to restore atrial kick
• Target heart rate <80 bpm if possible

O — OPTIMIZE the rhythm

• Atrial fibrillation with loss of atrial kick can precipitate LVOTO
• Cardioversion may be needed if hemodynamically unstable
• AV sequential pacing if indicated

P — POSITION the patient

• Trendelenburg increases venous return and preload
• Simple but often overlooked intervention

FILL — Volume resuscitate

• Increase preload to distend the LV cavity and widen the LVOT
• Crystalloid boluses (250-500 mL), guided by IVC assessment and lung ultrasound
• Caution: do not fluid-overload — use echo to guide

SQUEEZE — Augment afterload

• Phenylephrine (pure alpha agonist) is ideal — increases afterload without increasing contractility
• Vasopressin is an excellent alternative — Balik et al. showed vasopressin reduced LVOT gradients from 78 to 35 mmHg (p=0.01) while allowing norepinephrine weaning (PMID: 32488425)
• Norepinephrine is acceptable but has some beta-1 activity

Decision Point: Which vasopressor for LVOTO?

Say Out Loud: "This patient has dynamic LVOTO. I need to STOP inotropes, FILL the tank with volume, and SQUEEZE the afterload up with phenylephrine or vasopressin. No dobutamine, no milrinone."

Teaching Point: Jentzer et al. provided a useful conceptual framework: LVOTO behaves like a stenotic lesion, requiring the same hemodynamic approach as aortic stenosis — maintain preload, maintain afterload, maintain sinus rhythm, avoid tachycardia. This is the opposite of regurgitant lesions which benefit from afterload reduction and inotropes (PMID: 32314662).

Clinical Cases

Case 1: The Septic Patient Who Got Worse on Dobutamine

%%FIG5%% Presentation: A 72-year-old man with a history of hypertension and type 2 diabetes presents with urosepsis. HR 125, BP 75/40, lactate 6.2 mmol/L. He receives 30 mL/kg crystalloid with minimal improvement. The ICU team starts norepinephrine 0.15 mcg/kg/min, then adds dobutamine 5 mcg/kg/min for presumed septic cardiomyopathy.

The Deterioration: Within 20 minutes of starting dobutamine, BP drops to 60/30. HR rises to 140. Lactate climbs to 8.1.

Audience Poll: What would you do next?

• A) Increase the dobutamine — the heart needs more support
• B) Add vasopressin
• C) Perform bedside echocardiography
• D) Prepare for intubation and central line

The Echo: Bedside PLAX view reveals a thick-walled, hyperdynamic LV with near-cavity obliteration. SAM of the anterior mitral valve leaflet is clearly visible. CW Doppler shows a peak gradient of 85 mmHg across the LVOT. Severe posteriorly-directed MR.

Management: Dobutamine is stopped immediately. Phenylephrine infusion is started at 100 mcg/min. A 500 mL crystalloid bolus is given over 15 minutes. Within 30 minutes: BP improves to 95/55, HR decreases to 100, LVOT gradient drops to 25 mmHg.

Outcome: The patient is managed with phenylephrine and careful volume optimization. Antibiotics clear the infection over 72 hours. The LVOT gradient resolves completely with euvolemia. Echo at discharge shows mild concentric LV hypertrophy — the substrate that was always there, unmasked by sepsis.

Key Teaching Point: This patient had subclinical LV hypertrophy from decades of hypertension. Sepsis provided all four triggers: hypovolemia, tachycardia, low afterload, and then the dobutamine completed the perfect storm. The echo took 2 minutes and changed everything.

Case 2: The Post-Surgical Crash — LVOTO After Mitral Valve Repair

%%FIG6%% Presentation: A 58-year-old woman is 6 hours post-mitral valve repair for severe mitral regurgitation. She was hemodynamically stable in the cardiac ICU but now develops sudden hypotension: BP 70/35, HR 130, CVP 4 mmHg. Mixed venous O2 is 52%.

The Team's Initial Response: Milrinone is started for presumed post-cardiotomy low cardiac output syndrome.

The Deterioration: BP drops further to 55/30. New systolic murmur heard at the apex.

The Echo: TEE reveals SAM of the anterior mitral valve leaflet with significant LVOT obstruction (gradient 65 mmHg). Severe MR directed posteriorly. LV is hyperdynamic with small cavity.

Management: Milrinone is stopped. Volume resuscitation with 1L crystalloid. Phenylephrine boluses followed by infusion. Esmolol 500 mcg/kg bolus then 50 mcg/kg/min infusion. LVOT gradient decreases to 15 mmHg over 45 minutes.

Key Teaching Point: Post-mitral valve repair patients are particularly susceptible to LVOTO. The repair often narrows the LVOT, and the postoperative state combines hypovolemia, tachycardia, and inotrope use. Every post-MVR patient who becomes hypotensive needs an echo before escalating inotropes.

Case 3: Refractory Shock — The Takotsubo Surprise

%%FIG7%% Presentation: A 67-year-old woman presents after the sudden death of her spouse. She reports crushing chest pain. ECG shows diffuse ST elevations. Troponin is mildly elevated at 0.8 ng/mL. Cath lab shows clean coronaries. Echo shows classic apical ballooning with basal hypercontractility — Takotsubo syndrome.

The Complication: Despite IV fluids, she develops cardiogenic shock: BP 80/45, HR 115, cool extremities. Dobutamine is started.

The Deterioration: Within 1 hour, BP drops to 65/35. A new loud systolic murmur appears.

The Echo: Repeat echo shows the apical segments are akinetic (Takotsubo pattern), but the basal segments are hypercontractile. This basal hypercontractility has created dynamic LVOTO with a gradient of 72 mmHg. SAM and severe MR are present.

Management: Dobutamine is stopped. Esmolol is started cautiously. Volume resuscitation. Vasopressin is added for afterload support. Over 24 hours, the gradient decreases as Takotsubo begins to resolve.

Key Teaching Point: LVOTO complicates 6-20% of Takotsubo cases (Di Vece et al., PMID: 34362020). The mechanism is unique: apical akinesis forces all contractility into the basal segments, which then obstruct the LVOT. Vila-Sanjuan et al. found that LVOTO in Takotsubo shock is associated with significantly higher rates of ventricular arrhythmias and renal failure (PMID: 39209437). The instinct to support the failing heart with inotropes is exactly wrong.

Case 4: The Normal Heart — Catecholamine-Induced LVOTO

%%FIG8%% Presentation: A 45-year-old previously healthy woman presents in anaphylactic shock after a bee sting. She receives epinephrine 0.3 mg IM x2, then an epinephrine infusion at 0.1 mcg/kg/min for persistent hypotension. IV fluids are running wide open.

The Paradox: Despite epinephrine and fluids, BP remains 70/40. No wheezing, no angioedema — the anaphylaxis appears treated, but the hypotension persists.

The Echo: PLAX shows a structurally normal heart with no LV hypertrophy. But the ventricle is hyperdynamic — near-cavity obliteration. SAM is present. CW Doppler: LVOT gradient 55 mmHg.

Management: Epinephrine infusion is reduced to the minimum effective dose. Phenylephrine is substituted for hemodynamic support. Rapid fluid resuscitation continues. Within 20 minutes, gradient resolves and BP normalizes.

Key Teaching Point: This case demonstrates that LVOTO can occur in a structurally normal heart — catecholamine excess alone can create the obstruction (Mingo et al., PMID: 16290226). In the anaphylaxis context, the patient was already volume-depleted (third-spacing), vasodilated, and tachycardic. High-dose epinephrine added the final ingredient: excessive beta-1 stimulation. The treatment was reducing catecholamine dose and augmenting afterload with a pure alpha agonist.

Say Out Loud: "LVOTO doesn't require a thick heart. Any patient on high-dose catecholamines who isn't responding — consider the outflow tract."

Case 5: The Diagnostic Pivot — From Cardiogenic Shock to LVOTO

%%FIG9%% Presentation: A 78-year-old man with known aortic stenosis presents with acute heart failure. BP 82/50, HR 110, BNP 2,400. Initial bedside echo shows a thick LV with LVEF ~40%. The ED team starts a dobutamine drip for cardiogenic shock.

The Worsening: Over the next hour, the patient becomes more hypotensive and confused despite escalating dobutamine to 10 mcg/kg/min.

Audience Poll: This patient is getting worse on dobutamine. What is the most likely explanation?

• A) Progression of heart failure — needs more inotropic support
• B) Cardiogenic shock has progressed to distributive shock
• C) Dynamic LVOTO — the dobutamine is causing obstruction
• D) Sepsis superimposed on heart failure

The Pivot: A senior EM physician repeats the echo and specifically interrogates the LVOT. CW Doppler reveals a late-peaking, dagger-shaped velocity profile with a gradient of 90 mmHg — dynamic LVOTO superimposed on the aortic stenosis.

Management: Dobutamine is stopped. Fluid resuscitation (cautious, given the heart failure). Phenylephrine for afterload. Esmolol at low dose. Gradient decreases to 20 mmHg. Patient stabilizes for urgent cardiology consultation regarding aortic valve intervention.

Key Teaching Point: LVOTO can coexist with other cardiac pathology and be unmasked by well-intentioned therapy. The reduced LVEF of 40% was from the aortic stenosis — but the thick, hypertrophied LV was primed for dynamic obstruction once inotropes were added. Always interrogate the LVOT when inotropes fail.

Section 6: Post-Operative Considerations

Duration: 8 min | Content Tier: Nuance

%%FIG10%% Nuance: Post-cardiac surgery patients represent a special high-risk population for dynamic LVOTO due to multiple converging factors:

Why Surgery Creates Risk

1. Altered geometry: Mitral valve repair changes the spatial relationship between the mitral apparatus and the septum. Ring annuloplasty can redirect the anterior leaflet into the LVOT.

1. Hypovolemia: Post-bypass patients are frequently volume-depleted from hemodilution, third-spacing, and diuresis.

1. Catecholamine use: Inotropes are routinely used for post-cardiotomy low-output syndrome, creating the final trigger.

1. Sympathetic activation: Pain, emergence from anesthesia, and physiologic stress all increase endogenous catecholamine levels.

High-Risk Procedures

• Mitral valve repair — highest risk, especially with undersized annuloplasty rings
• Aortic valve replacement — altered LVOT geometry
• Septal myectomy — can create or unmask SAM
• CABG in patients with LVH — post-bypass hemodynamics may trigger LVOTO

Teaching Point: The key diagnostic clue is the post-cardiac surgery patient whose hemodynamics worsen with inotropes. If you find yourself escalating dobutamine or milrinone and the patient keeps declining — stop, echo, and look at the LVOT.

Section 7: Future Directions

Duration: 5 min | Content Tier: Teaching Point

What's Coming

• AI-assisted LVOTO detection: Machine learning algorithms that automatically screen for SAM and elevated LVOT gradients during routine bedside echo — similar to AI-LVEF tools already in use
• Continuous hemodynamic monitoring: Wearable or indwelling ultrasound arrays that track LVOT gradient in real-time during vasopressor titration
• Simulation-based training: VR ultrasound simulators that allow trainees to practice identifying LVOTO in realistic clinical scenarios
• POCUS accreditation: Harrington et al. argued that LVOT assessment should be added to critical care echo accreditation requirements — a change that is gaining traction internationally (PMID: 37287244)
• Updated sepsis guidelines: Future iterations of the Surviving Sepsis Campaign will likely incorporate routine echocardiographic phenotyping to guide vasopressor and inotrope selection

Audience Poll: What would most improve LVOTO detection in your practice?

• A) Mandatory bedside echo before starting inotropes
• B) AI-assisted LVOTO screening during all POCUS exams
• C) Better simulation training for identifying SAM
• D) Updated sepsis protocols that include echo phenotyping

Tonight on Shift

When you walk into the department tonight, remember these six things:

1. Dynamic LVOTO is the great masquerader — it mimics cardiogenic shock but requires the opposite treatment. Prevalence in septic shock is ~2%, but mortality reaches 53% when missed.

1. Look at the LVOT before starting inotropes — a 30-second PLAX view can prevent a catastrophic error. SAM, hyperdynamic LV, and dagger-shaped CW Doppler are your diagnostic triad.

1. STOP-FILL-SQUEEZE — Stop inotropes. Fill with volume. Squeeze afterload with phenylephrine or vasopressin. This is the opposite of cardiogenic shock management and that's the whole point.

1. LVOTO can happen in normal hearts — you don't need HCM. Catecholamine excess alone can create obstruction. Any patient on high-dose vasopressors who isn't responding should get an echo.

1. Vasopressin is your friend — it augments afterload without beta-1 stimulation. Balik et al. showed it reduces LVOT gradients by 55% (78 → 35 mmHg).

1. Post-cardiac surgery patients are high-risk — especially post-mitral valve repair. If they deteriorate on inotropes, think LVOTO before you think "they need more."

References

1. Balik M, et al. Vasopressin in patients with septic shock and dynamic left ventricular outflow tract obstruction. Cardiovasc Drugs Ther. 2020;34(5):685-688. PMID: 32488425.
2. Slama M, Tribouilloy C, Maizel J. Left ventricular outflow tract obstruction in ICU patients. Curr Opin Crit Care. 2016;22(3):260-266. PMID: 27054628.
3. Evans LR, et al. Left ventricular outflow tract obstruction — be prepared! Anaesth Intensive Care. 2017;45(1):12-20. PMID: 28072930.
4. Li X, et al. Dynamic LVOT obstruction in critical illness: etiology-driven management and bedside TTE. Crit Care. 2025;29(1):510. PMID: 41316420.
5. Long B, et al. Left ventricular outflow tract obstruction: a narrative review for emergency clinicians. Am J Emerg Med. 2025;98:153-159. PMID: 40876217.
6. Bughrara N, Diaz-Gomez JL, Pustavoitau A. Perioperative management of patients with sepsis: ultrasound support for resuscitation. Anesthesiol Clin. 2020;38(1):123-134. PMID: 32008647.
7. Harrington D, Aron J, Lashin A. Focused 2D echo in managing LVOTO mimicking cardiogenic shock. J Intensive Care Med. 2023;38(10):897-902. PMID: 37287244.
8. Mingo S, et al. Dynamic LVOTO secondary to catecholamine excess in a normal ventricle. Int J Cardiol. 2006;112(3):393-396. PMID: 16290226.
9. Di Vece D, et al. Dynamic left intraventricular obstruction phenotype in Takotsubo syndrome. J Clin Med. 2021;10(15):3235. PMID: 34362020.
10. Vila-Sanjuan S, et al. LVOTO in Takotsubo syndrome with cardiogenic shock: prognosis and treatment. Heart. 2024;110(23):1381-1388. PMID: 39209437.
11. Jentzer JC, et al. Structural heart disease emergencies. J Intensive Care Med. 2021;36(9):975-988. PMID: 32314662.

Read this seminar as Markdown · All seminars · Lecture library · Question bank